In this study, for the first time, we validated that the combination of ZA and rapamycin, targeting on the mTOR and mevalonate pathways, could eliminate the tumors and inhibit tumor recurrence in the LAM mouse models. Here, MTOR is linked to lymphangioleiomyomatosis.